Top

Published in:

01-12-2022 | Severe Acute Respiratory Syndrome Coronavirus | Brief Report

Identification and application of a pair of noncompeting monoclonal antibodies broadly binding to the nucleocapsid proteins of SARS-CoV-2 variants including Omicron

Authors: Bing Zhou, Lin Cheng, Shuo Song, Huimin Guo, Senlin Shen, Haiyan Wang, Xiangyang Ge, Lei Liu, Bin Ju, Zheng Zhang

Published in: Virology Journal | Issue 1/2022

Abstract

The SARS-CoV-2 nucleocapsid protein (NP) is an important indicator for the virus infection, highlighting the crucial role of NP-specific monoclonal antibodies (mAbs) used in multiple biochemical assays and clinical diagnosis for detecting the NP antigen. Here, we reported a pair of noncompeting human NP-specific mAbs, named P301-F7 and P301-H5, targeting two distinct linear epitopes on SARS-CoV-2 or SARS-CoV. We evaluated the application of P301-F7 in the analysis of enzyme linked immunosorbent assay, western blot, flow cytometry, immunofluorescence, and focus reduction neutralization test. We for the first time report a broad mAb effectively recognizing various live viruses of SARS-CoV-2 variants including Alpha, Beta, Delta, and Omicron, indicating a wide range of application prospects.

Available only for authorised users

Zhu N, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33. https://doi.org/10.1056/NEJMoa2001017.CrossRefPubMedPubMedCentral

Drosten C, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348:1967–76. https://doi.org/10.1056/NEJMoa030747.CrossRefPubMed

Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–20. https://doi.org/10.1056/NEJMoa1211721.CrossRefPubMed

Lu R, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet (London, England). 2020;395:565–74. https://doi.org/10.1016/s0140-6736(20)30251-8.CrossRef

Ju B, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020. https://doi.org/10.1038/s41586-020-2380-z.CrossRefPubMedPubMedCentral

Wang R, et al. Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. Immunity. 2021. https://doi.org/10.1016/j.immuni.2021.06.003.CrossRefPubMedPubMedCentral

Wang P, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021. https://doi.org/10.1038/s41586-021-03398-2.CrossRefPubMedPubMedCentral

Liu C, et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021. https://doi.org/10.1016/j.cell.2021.06.020.CrossRefPubMedPubMedCentral

Cheng L, et al. Cross-neutralization of SARS-CoV-2 Kappa and Delta variants by inactivated vaccine-elicited serum and monoclonal antibodies. Cell Discov. 2021;7:112. https://doi.org/10.1038/s41421-021-00347-1.CrossRefPubMedPubMedCentral

10.

Wu H, et al. Nucleocapsid mutations R203K/G204R increase the infectivity, fitness, and virulence of SARS-CoV-2. Cell Host Microbe. 2021. https://doi.org/10.1016/j.chom.2021.11.005.CrossRefPubMedPubMedCentral

11.

Syed AM, et al. Rapid assessment of SARS-CoV-2 evolved variants using virus-like particles. Science. 2021. https://doi.org/10.1126/science.abl6184.CrossRefPubMedPubMedCentral

12.

Liu SJ, et al. Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates. Vaccine. 2006;24:3100–8. https://doi.org/10.1016/j.vaccine.2006.01.058.CrossRefPubMedPubMedCentral

13.

Dutta NK, Mazumdar K, Gordy JT. The nucleocapsid protein of SARS-CoV-2: a target for vaccine development. J Virol. 2020. https://doi.org/10.1128/jvi.00647-20.CrossRefPubMedPubMedCentral

14.

Terry JS, et al. Development of a SARS-CoV-2 nucleocapsid specific monoclonal antibody. Virology. 2021;558:28–37. https://doi.org/10.1016/j.virol.2021.01.003.CrossRefPubMed

15.

Yamaoka Y, et al. Highly specific monoclonal antibodies and epitope identification against SARS-CoV-2 nucleocapsid protein for antigen detection tests. Cell Rep Med. 2021;2: 100311. https://doi.org/10.1016/j.xcrm.2021.100311.CrossRefPubMedPubMedCentral

16.

Tian X, et al. Epitope mapping of severe acute respiratory syndrome-related coronavirus nucleocapsid protein with a rabbit monoclonal antibody. Virus Res. 2021;300: 198445. https://doi.org/10.1016/j.virusres.2021.198445.CrossRefPubMedPubMedCentral

17.

Kang S, et al. A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation. Nat Commun. 2021;12:2697. https://doi.org/10.1038/s41467-021-23036-9.CrossRefPubMedPubMedCentral

18.

Ju B, et al. Identification of a novel broadly HIV-1-neutralizing antibody from a CRF01_AE-infected Chinese donor. Emerg Microbes Infect. 2018;7:174. https://doi.org/10.1038/s41426-018-0175-1.CrossRefPubMedPubMedCentral

19.

Zhang Q, et al. Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2. Nat Commun. 2021;12:4210. https://doi.org/10.1038/s41467-021-24514-w.CrossRefPubMedPubMedCentral

20.

Burbelo PD, et al. Sensitivity in detection of antibodies to nucleocapsid and spike proteins of severe acute respiratory syndrome coronavirus 2 in patients with coronavirus disease 2019. J Infect Dis. 2020;222:206–13. https://doi.org/10.1093/infdis/jiaa273.CrossRefPubMed

21.

Zhang L, et al. Development of patient-derived human monoclonal antibodies against nucleocapsid protein of severe acute respiratory syndrome coronavirus 2 for coronavirus disease 2019 diagnosis. Front Immunol. 2020;11:595970. https://doi.org/10.3389/fimmu.2020.595970.CrossRefPubMedPubMedCentral

22.

Xie C, et al. Preparation of highly specific monoclonal antibodies against SARS-CoV-2 nucleocapsid protein and the preliminary development of antigen detection test strips. J Med Virol. 2022;94:1633–40. https://doi.org/10.1002/jmv.27520.CrossRefPubMed

23.

Zeng W, et al. Biochemical characterization of SARS-CoV-2 nucleocapsid protein. Biochem Biophys Res Commun. 2020;527:618–23. https://doi.org/10.1016/j.bbrc.2020.04.136.CrossRefPubMedPubMedCentral

24.

Gransagne M, et al. Development of a highly specific and sensitive VHH-based sandwich immunoassay for the detection of the SARS-CoV-2 nucleoprotein. J Biol Chem. 2022;298: 101290. https://doi.org/10.1016/j.jbc.2021.101290.CrossRefPubMed

25.

Planas D, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021. https://doi.org/10.1038/s41586-021-03777-9.CrossRefPubMed

26.

Liu L, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2021. https://doi.org/10.1038/d41586-021-03826-3.CrossRefPubMedPubMedCentral

Title: Identification and application of a pair of noncompeting monoclonal antibodies broadly binding to the nucleocapsid proteins of SARS-CoV-2 variants including Omicron
Authors: Bing Zhou
Lin Cheng
Shuo Song
Huimin Guo
Senlin Shen
Haiyan Wang
Xiangyang Ge
Lei Liu
Bin Ju
Zheng Zhang
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Severe Acute Respiratory Syndrome Coronavirus
SARS-CoV-2
Published in: Virology Journal / Issue 1/2022
Electronic ISSN: 1743-422X
DOI: https://doi.org/10.1186/s12985-022-01827-w

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2022

Sensitive and specific serological ELISA for the detection of SARS-CoV-2 infections

Enhanced synergistic antitumor effect of a DNA vaccine with anticancer cytokine, MDA-7/IL-24, and immune checkpoint blockade

The underlying mechanism of Guillain-Barré syndrome in a young patient suffered from Japanese encephalitis virus infection: a case report

Whole-genome sequence analysis reveals the circulation of multiple SARS-CoV-2 variants of concern in Nairobi and neighboring counties, Kenya between March and July 2021

Human papillomavirus prevalence and genotype distribution landscapes in Shannan City, Tibet Tibetan Autonomous Region, China

Establishment and evaluation of a quadruple quantitative real-time PCR assay for simultaneous detection of human coronavirus subtypes

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage